In spite of macro uncertainties, healthcare mergers, acquisitions, JVs and other transactions – especially in the MedTech space – are poised to increase, driven by several industry fundamentals.
In an article for MedTech Dive, Nemphos Braue’s Caroline Popper highlights 5 Reasons Why MedTech M&A is Poised for Growth.
And here’s one hint: AI isn’t the (only) factor. Roll-ups, patient demands, a need for efficiency and more will contribute to increased activity.
Read about Nemphos Braue’s work with medtech innovator Amalgam Rx.
MedTech is a market segment that is accelerating, with transactions occurring at the intersection of services, technologies and data science. An unprecedented increase in the understanding of biology enables more personalization and precision in medicine, and that innovation necessitates more efficiency to move forward, faster.
1. There is hot competition for truly innovative assets.
Innovation is paramount in any industry, but when it comes to expediting advancements in healthcare, extending the lives of those with terminal illnesses and debilitating diseases, or enabling providers to improve quality of care, it’s literally lifesaving.
